{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:25:01Z","timestamp":1789183501994,"version":"build-2803163510"},"reference-count":28,"publisher":"Massachusetts Medical Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NEJM Catalyst"],"published-print":{"date-parts":[[2026,7,15]]},"DOI":"10.1056\/cat.25.0416","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:45:11Z","timestamp":1784119511000},"source":"Crossref","is-referenced-by-count":1,"title":["Cancer Immunotherapy Stewardship \u2014 Cost-Neutral, Patient-Centered Dosing to Increase Infusion Center Efficiency"],"prefix":"10.1056","volume":"7","author":[{"given":"Julie A.","family":"Moeller","sequence":"first","affiliation":[{"name":"Oncology Pharmacist, Division of Oncology, LTC Charles S Kettles VA Medical Center, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Gyori","sequence":"additional","affiliation":[{"name":"Oncology Pharmacist, Division of Oncology, LTC Charles S Kettles VA Medical Center, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Gau","sequence":"additional","affiliation":[{"name":"Resident Physician, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth W.","family":"Strohbehn","sequence":"additional","affiliation":[{"name":"Investigator, VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, USA"},{"name":"Assistant Professor of Internal Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA"},{"name":"Member, Rogel Comprehensive Cancer Center, Department of Medicine, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_3_2_2","unstructured":"Centers for Medicare & Medicaid Services. Medicare part B drug spending dashboard. December 31 2023. Accessed April 23 2026 (https:\/\/data.cms.gov\/tools\/medicare-part-b-drug-spending-dashboard)."},{"key":"e_1_3_3_3_2","unstructured":"U.S. Food and Drug Administration. Package insert \u2014 KEYTRUDA (pembrolizumab). Initial U.S. approval: 2014. September 2014. Accessed April 4 2026 (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125514lbl.pdf)."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i788"},{"key":"e_1_3_3_5_2","unstructured":"U.S. Food and Drug Administration. Package insert \u2014 KEYTRUDA (pembrolizumab). Supplemental BLA 12. October 2016. Accessed April 4 2026 (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125514s012lbl.pdf)."},{"key":"e_1_3_3_6_2","unstructured":"U.S. Food and Drug Administration. Supplement approval fullfillment [sic] of postmarketing commitment BLA 125514\/S-13. May 17 2017 (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/125514Orig1s013ltr.pdf)."},{"key":"e_1_3_3_7_2","unstructured":"U.S. Food and Drug Administration. FDA approves new dosing regimen for pembrolizumab. April 29 2020. Accessed April 4 2026 (https:\/\/wayback.archive-it.org\/7993\/20201220145731\/https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-new-dosing-regimen-pembrolizumab)."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2592"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-PS4-07-12"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx063"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.00102"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231212926"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.4109"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","unstructured":"Goldstein DA Ginsberg GM Hofnung- Gabbay D et al. Multinational analysis of estimated health care costs related to extended- interval fixed dosing of checkpoint inhibitors. JAMA Netw Open 2023;6:e230490. DOI: 10.1001\/jamanetworkopen.2023.0490.","DOI":"10.1001\/jamanetworkopen.2023.0490"},{"key":"e_1_3_3_15_2","unstructured":"Walker S de L\u00e9s\u00e9leuc S Butcher R. CADTH technology review: optimal use 360 report: dosing and timing of immuno-oncology drugs. Canadian Agency for Drugs and Technologies in Health. Issue 25. November 2019 (https:\/\/www.cadth.ca\/sites\/default\/files\/ou-tr\/ho0008-dosing-timing-immuno-oncology-drugs.pdf)."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00554-x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0257"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04181-0"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107950"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1315"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.0703"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01015"},{"key":"e_1_3_3_23_2","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology\u2013breast cancer version 4.2025. Section BINV-M. 2025 (https:\/\/www.scribd.com\/document\/941014534\/Breast-Guidelines)."},{"key":"e_1_3_3_24_2","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology\u2013colon cancer version 2. Section COL-D 2026 (https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1428)."},{"key":"e_1_3_3_25_2","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology \u2014 occult primary version 1. Section OCC-B 2025 (https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1451)."},{"key":"e_1_3_3_26_2","unstructured":"Langreth R. Pharma is pushing $200 000 cancer drugs when cheaper doses may work. Bloomberg News. September 24 2025 (https:\/\/www.bloomberg.com\/features\/2025-experimental-cheaper-treatments-cancer-capitalism\/)."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.25270\/jcp.2025.07.01"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02810"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115373"}],"container-title":["NEJM Catalyst"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:45:42Z","timestamp":1784119542000},"score":1,"resource":{"primary":{"URL":"https:\/\/catalyst.nejm.org\/doi\/10.1056\/CAT.25.0416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,15]]}},"alternative-id":["10.1056\/CAT.25.0416"],"URL":"https:\/\/doi.org\/10.1056\/cat.25.0416","relation":{},"ISSN":["2642-0007"],"issn-type":[{"value":"2642-0007","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,15]]}}}